2020 Volume 20 Issue 3 Pages 160-167
Hereditary breast and ovarian cancer syndrome (HBOC) has a high lifetime morbidity of breast and ovarian cancers based on BRCA1/2 pathogenic variants. Properly selecting patients and diagnosing HBOC by genetic counseling and genetic testing will enable surveillance and preventive intervention for not only patients, but also their family members. Risk reduction salpingo-oophorectomy (RRSO) is the only highly recommended ovarian cancer prophylaxis for carriers of BRCA1/2 pathogenic variants. The gynecology department of our hospital performed laparoscopic RRSO for HBOC as a clinical study, "Evaluation of risk-reduction surgery for hereditary breast and ovarian cancer syndrome", after approval from our ethics review committee in January 2017. We analyzed issues from our experience of RRSO at this hospital, and examined HBOC cases in which RRSO was not performed and follow-up is ongoing.